A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma

Full Title

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Non-Hodgkin’s B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia


The purpose of this study is to find the highest dose of the investigational drug MT-3724 that can be given safely in patients with relapsed B-cell non-Hodgkin lymphoma (NHL). MT-3724 is an “immunotoxin.” It is designed to kill NHL B cells by targeting a protein on the cancer cell surface called CD20. After targeting CD20, MT-3724 enters the cell and releases a toxin that prevents the cancer cell from making proteins it needs to survive. This causes the cancer cell to die.

MT-3724 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have B-cell NHL that returned despite prior therapy with a CD20-targeted drug other than MT-3724.
  • Patients should have exhausted all other standard treatment options for their cancer.
  • At least 4 weeks must pass between the completion of previous treatment and entry into this study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Paul A. Hamlin at 212-639-6143.